Tirzepatide targets two receptors (GLP-1 and GIP). Retatrutide targets three receptors (GLP-1, GIP and glucagon). The additional glucagon receptor targeting in Retatrutide is believed to be responsible for the significantly greater results seen in Phase 2 clinical trials. Retatrutide showed 24.2% average results vs approximately 20.9% for Tirzepatide at comparable doses.
Canadian researchers interested in the most advanced GLP-1/GIP compound consistently choose Retatrutide over Tirzepatide based on Phase 2 data. Both compounds are available at Boreals Peptides with Canada Post Xpresspost to all provinces. Free shipping over CA$200. Pen and vial format available.